FDA approves new hyaluronidase formula

December 15, 2005

Rockville, MD—The FDA has approved PrimaPharm Inc.'s new drug application for a new formulation for hyaluronidase injection (Hydase).

Rockville, MD-The FDA has approved PrimaPharm Inc.'s new drug application for a new formulation for hyaluronidase injection (Hydase).

The prescription drug was approved as an adjuvant to increase the absorption and dispersion of other injected drugs, for hypodermoclysis, and as an adjunct in subcutaneous urography for improving resorption of radiopaque agents.

The FDA said it is a proteolytic enzyme and reviewed under a priority review cycle.